Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.43 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991879 | 0.85 | GHSR (0.46) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL187518 | 0.85 | KDM4E (0.47) | DAONR3C1PGRNR3C2AHR | |
| SCHEMBL7404447 | 0.82 | GHSR (0.54) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL5795144 | 0.81 | DAO (0.51) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL1381430 | 0.81 | DAO (0.47) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL10412904 | 0.78 | MAPT (0.64) | DAODDOMAPTRXFP1FLT3 | |
| SCHEMBL11812311 | 0.78 | IDO1 (0.53) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL30667472 | 0.78 | IDO1 (0.53) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL6990951 | 0.78 | DAO (0.49) | DAODDONR3C1PGRNR3C2 | |
| SCHEMBL29991828 | 0.78 | HTR2C (0.47) | DAODDONR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025037229-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-05-26 | — | — | US | disclosed |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| CN-108794468-A | A kind of preparation method of Tetrahydropyridoindocompounds compounds | 新发药业有限公司 | 2018-11-13 | — | — | CN | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| EP-1687294-B1 | NOVEL PIPERIDINE-SUBSTITUTED INDOLES-OR HETERO-DERIVATIVES THEREOF AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR (CCR-3) | BOEHRINGER INGELHEIM INT (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759365-B2 | Piperidine-substituted indoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| US-7544806-B2 | Piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| CN-101119747-A | Tissue factor production inhibitor | SANKYO CO (JP) | 2008-02-06 | — | — | CN | disclosed |
| CN-1882565-A | Novel piperidine-substituted indoles-or hetero-derivatives thereof and their use as modulators of chemokine receptor (CCR-3) | BOEHRINGER INGELHEIM INT (DE) | 2006-12-20 | — | — | CN | disclosed |
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662183-B2 | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same | SREBF1, SREBF2, BPTF | DAO 4332/4885DDO 3888/4885NR3C1 230/4885 |
| US-20250092036-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK | MAPK1, MAP3K1, MAPK6 | DAO 4622/4885DDO 4201/4885NR3C1 1065/4885 |
| US-20050153979-A1 | Novel piperidine-substituted indoles-or heteroderivatives thereof | CCR3, CCR1, CCR2 | DAO 2490/4885DDO 3893/4885NR3C1 585/4885 |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | NQO1, COQ8A, NDUFAB1 | DAO 1029/4885DDO 339/4885NR3C1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.